How Antibody Drug Conjugates are Fighting Cancer: Seattle’s Role & What’s Next

For over a century, immunologists have envisioned using Antibody Drug Conjugates (ADCs) to precisely target cancer cells with cell-killing payloads. However, it wasn’t until 2000 that the first ADC received FDA approval with limited success. Now most recently, multiple ADCs have gained additional approvals and are finally showing blockbuster potential. Interest is high with Pfizer acquiring ADC pioneer and Bothell headquartered, Seagen, for $43B last year and Genmab acquiring Seattle-based, ProfoundBio, for $1.8B.

Join our panel of regional experts as they discuss the long journey to success, Seattle’s role in shaping the field, and what the future holds for ADCs.

Members: $10
Non-Members: $50